Asthma Monitoring Options for the Digital Age
Price: FREE for members and non-members
Session recorded on January 27, 2022
Speaker: J. Allen Meadows, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this activity learners should be able to:
1. Verbalize the existence of remote monitoring devices
2. Recognize the benefits of entering a shared decision making process about digital inhalers with patients
3. List options for digital monitoring in asthma
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
J. Allen Meadows, MD, Speaker
Disclosures: Speaker: Regeneron, AstraZeneca, Sanofi, Optinose, Teva, Pfizer; Consultant: Takeda, Teva, Aimmune, ALK
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance